Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ABCL vs DAAQU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABCL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 9–1 Matrix Metrics)

ABCL Overall Winner 6-Pillar Tally: ABCL 4 – 1 DAAQU (1 Tie) Matrix Metrics: ABCL 9 – 1 DAAQU

As of Nov 19, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Digital Asset Acquisition Corp. Units (DAAQU) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABCL carries a Unified Composite Score of 58.6/100 (HOLD) at $10.47 (27.6x Forward P/E, -298.0% operating margin), whereas DAAQU carries 45.6/100 (HOLD) at $10.58 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ABCL is currently in a Breakdown options structure phase (RSI 38.4); meanwhile DAAQU trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABCL vs DAAQU
ABCL NASDAQ Head-to-Head Winner
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$10.47
-4.99% 1D
Market Cap $3.6B
TTM Revenue $68M
Forward P/E 27.6x
Beta / 30D Vol 2.30β · 85% Vol
Unified Composite Score
58.6 / 100 HOLD
Tech 36.0 Fund 59.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.4 · SMA20: $11.90 · SMA50: $12.32
DAAQU NASDAQ
Digital Asset Acquisition Corp. Units
Blank Checks
$10.58
+0.09% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.36β · 150% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (ABCL 4 – 1 DAAQU)

Columns: Metric · ABCL · DAAQU
1. Valuation Multiples ABCL
Forward P/E 27.6x N/M
Trailing P/E 27.6x N/M
PEG Ratio N/M N/M
EV / Revenue 52.6x N/M
2. Growth & Scale ABCL
Revenue Growth (YoY) +18.8% N/A
Earnings Growth (YoY) +45.9% N/A
TTM Revenue (USD) $68M N/A
Market Cap $3.6B N/A
3. Profitability & Quality ABCL
Gross Margin N/A N/A
Operating Margin -298.0% N/A
Net Profit Margin -218.6% N/A
Return on Equity (ROE) -14.6% N/A
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) -$33M N/A
Cash Flow Margin -48.4% N/A
Net Cash / Leverage $30M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DAAQU
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 80.5% (24th %ile) N/A (N/A)
Put/Call OI Skew 0.25x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Blank Checks Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABCL (9) vs DAAQU (1)
Institutional Metric ABCL DAAQU Criterion Row Edge
Market Capitalization
Scale
$3.6B N/A Larger Scale ABCL
Trailing P/E Ratio
Valuation
27.6x N/M Lower Multiple ABCL
Forward P/E Ratio
Valuation
27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY)
Growth
+18.8% N/A Higher Growth ABCL
Operating Margin (TTM)
Profitability
-298.0% N/A Higher Margin ABCL
Net Profit Margin
Profitability
-218.6% N/A Higher Margin ABCL
Return on Equity (ROE)
Capital Efficiency
-14.6% N/A Higher ROE ABCL
52-Week Range Position
Momentum
63% ($3–$15) 70% ($7–$12) Stronger Trend DAAQU
Beta / 30D Volatility
Risk Regime
2.30β · 85% Vol -0.36β · 150% Vol Lower Realized Risk ABCL
Unified Institutional Score
Composite Signal
58.6 / 100 (HOLD) 45.6 / 100 (HOLD) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
$68M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 52.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$33M ($30M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABCL +134.49 pp
ABCL: +134.77% · DAAQU: +0.28%
3M Horizon ABCL +156.1 pp
ABCL: +157.54% · DAAQU: +1.44%
6M Horizon ABCL +243.55 pp
ABCL: +245.38% · DAAQU: +1.83%
1Y Horizon ABCL +243.55 pp
ABCL: +245.38% · DAAQU: +1.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs DAAQU. Trailing 12-month operating profitability (ABCL -298.0% vs DAAQU N/A) and valuation multiples (ABCL 27.6x vs DAAQU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$68M
Gross MarginN/A
Op. Margin-298.0%
ROE / Fwd P/E-14.6% · 27.6x
DAAQU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABCL BREAKDOWN
37d in phase · OBV DISTRIBUTION
Current IV 80.5%
IV Percentile 24th %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DAAQU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DAAQU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $11.12 · IV 84.0%

ABCL Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,112)

Compare $1,112 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 84.0% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $12 / $13 Bull Call Spread

Buy 4x $12C · Sell 4x $13C · 32d

Net Entry $80 Debit
T+5d @ +5% Move +$25 (+31%)
Max Risk / Buffer $80 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $10 / $9 Bull Put Spread

Sell 5x $10P · Buy 5x $9P · 60d

Net Entry $175 Credit
Max Credit / Yield +$175 (+53.8% RoM)
Max Risk / Buffer -13.2% Cushion ($325 Mgn)
5d Edge & Liquidity 70% PoP · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $12 / $10 Bear Put Spread

Buy 1x $12P · Sell 1x $10P · 32d

Net Entry $106 Debit
T+5d @ -5% Drop +$16 (+15%)
Max Risk / Buffer $106 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and -298.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DAAQU Moat Profile Cyclical / Execution-Driven Positioning
Blank Checks Operator
Competes within the Blank Checks value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABCL vs DAAQU Key Questions & Quantitative Answers

As of Nov 19, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Digital Asset Acquisition Corp. Units (DAAQU) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABCL carries a Unified Composite Score of 58.6/100 (HOLD) at $10.47 (27.6x Forward P/E, -298.0% operating margin), whereas DAAQU carries 45.6/100 (HOLD) at $10.58 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ABCL is currently in a Breakdown options structure phase (RSI 38.4); meanwhile DAAQU trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABCL leads the Growth & Scale pillar: ABCL posts +18.8% YoY revenue growth and +45.9% YoY earnings growth on $68M TTM revenue (N/A gross margin, -298.0% operating margin), compared with DAAQU at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABCL generates $68M in USD-normalized revenue versus N/A for DAAQU. In operating R&D and SG&A reinvestment, ABCL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DAAQU.

ABCL screens cheaper on headline valuation multiples. ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 52.6x EV/Revenue (-48.4% FCF margin), whereas DAAQU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABCL (-14.6% ROE) versus DAAQU (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ABCL carries 80.5% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 85% Vol realized risk). By comparison, DAAQU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.36β · 150% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.